Investigating a new vaccine for Venezuelan Equine Encephalitis in healthy adults
Safety and Immunogenicity of novel, live-attenuated V4020 vaccine for Venezuelan Equine Encephalitis (VEE) in healthy adults
This study is testing a new vaccine called V4020 to see if it can safely protect healthy adults from the Venezuelan Equine Encephalitis virus, aiming to be a better option than the current vaccine.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medigen, INC. NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project ID | NIH-10815801 on NIH RePORTER |
What this research studies
This research focuses on developing a novel vaccine, V4020, to protect against Venezuelan Equine Encephalitis virus (VEEV), which poses a significant health threat. The vaccine is designed to be safer and more effective than the currently used TC-83 vaccine, which has known adverse effects. Healthy adult participants will receive the vaccine to assess its safety and immune response. The study aims to ensure that the vaccine does not revert to a pathogenic form, thereby providing a reliable option for outbreak control.
Who could benefit from this research
Good fit: Ideal candidates for participation are healthy adults aged 21 and older who are willing to receive the vaccine and participate in follow-up assessments.
Not a fit: Patients with pre-existing health conditions or those who are immunocompromised may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safer and more effective vaccine against Venezuelan Equine Encephalitis, protecting individuals from this serious infection.
How similar studies have performed: Previous research has shown promise in developing vaccines for similar viral infections, indicating potential success for this novel approach.
Where this research is happening
Frederick, United States
- Medigen, INC. — Frederick, United States (Active)
Researchers
- Principal investigator: Pushko, Peter M. — Medigen, INC.
- Study coordinator: Pushko, Peter M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.